The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has...
Main Authors: | Grace Cuddihy, Ellen K. Wasan, Yunyun Di, Kishor M. Wasan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/11/3/99 |
Similar Items
-
Standart and Lipozomal Amphotericin B in Febrile Neutropenia with Hematological Malignancies
by: H. Şenol COŞKUN, et al.
Published: (1998-06-01) -
Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review
by: N. V. Dmitrieva, et al.
Published: (2014-07-01) -
Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review
by: N. V. Dmitrieva, et al.
Published: (2014-07-01) -
Intralipid efficacy in decreasing Amphotericin B associated nephrotoxicity
by: Hasibi M, et al.
Published: (2013-03-01) -
Delivery strategies of amphotericin B for invasive fungal infections
by: Xiaochun Wang, et al.
Published: (2021-08-01)